Wiseman, Jessica P
Scarrott, Joseph M
Alves-Cruzeiro, João
Saffari, Afshin https://orcid.org/0000-0003-4119-7519
Böger, Cedric
Karyka, Evangelia https://orcid.org/0000-0001-5551-6109
Dawes, Emily
Davies, Alexandra K https://orcid.org/0000-0002-1594-8780
Marchi, Paolo M https://orcid.org/0000-0002-8893-3790
Graves, Emily
Fernandes, Fiona https://orcid.org/0009-0000-3383-6363
Yang, Zih-Liang
Coldicott, Ian https://orcid.org/0000-0002-1919-7419
Hirst, Jennifer
Webster, Christopher P https://orcid.org/0000-0003-4197-2036
Highley, J Robin
Hackett, Neil https://orcid.org/0009-0006-9184-4437
Angyal, Adrienn
Silva, Thushan de
Higginbottom, Adrian
Shaw, Pamela J https://orcid.org/0000-0002-8925-2567
Ferraiuolo, Laura
Ebrahimi-Fakhari, Darius
Azzouz, Mimoun https://orcid.org/0000-0001-6564-5967
Funding for this research was provided by:
LifeArc (163978 and P2022-0004)
Innovative Health Initiative (945473)
Alzheimer's Research UK (ARUK-PG2018B-005)
UKRI | Medical Research Council (MR/V030140/1)
UKRI | Medical Research Council (MR/W00416X/10)
UKRI | Medical Research Council (MR/V000470/1)
NIHR | NIHR Sheffield Biomedical Research Centre
EC | European Research Council (294745)
CureAP4 foundation
Spastic Paraplegia Foundation
HHS | NIH | National Institute of Neurological Disorders and Stroke (K08NS123552-01)
Article History
Received: 15 March 2024
Revised: 17 September 2024
Accepted: 19 September 2024
First Online: 2 October 2024
Disclosure and competing interests statement
: MA is co-founder of BlackfinBio and Crucible Therapeutics. NH is a paid consultant to CureAP4. PJS is co-founder of Keapstone Therapeutics and Crucible Therapeutics.